Improving Care Through Azithromycin Research for Infants in Africa (ICARIA)
Evaluation of the Impact on Childhood Mortality of Azithromycin Plus Intermittent Preventive Treatment Administered Through the Expanded Program on Immunization in Sierra Leone
Sponsor: Barcelona Institute for Global Health
Listed as NCT04235816, this PHASE3 trial focuses on Child Mortality and remains ongoing. Sponsored by Barcelona Institute for Global Health, it has been updated 11 times since 2021, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Aug 2025 — Present [monthly]
Active Not Recruiting PHASE3
-
Jul 2025 — Aug 2025 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Sep 2024 — Jul 2025 [monthly]
Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE3
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE3
▶ Show 6 earlier versions
-
Oct 2023 — Jun 2024 [monthly]
Recruiting PHASE3
-
Oct 2021 — Oct 2023 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Mar 2021 — Oct 2021 [monthly]
Not Yet Recruiting PHASE3
-
Jan 2021 — Mar 2021 [monthly]
Not Yet Recruiting PHASE3
-
Nov 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE3
-
Feb 2020 — Nov 2020 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Barcelona Institute for Global Health
- Bill and Melinda Gates Foundation
- La Caixa Foundation
- Ministry of Health and Sanitation, Sierra Leone
- University of Sierra Leone
For direct contact, visit the study record on ClinicalTrials.gov .